BioCentury
ARTICLE | Finance

Room to rally in 2Q

Biotech out-performance could continue in 2Q if M&A rally keeps up

April 6, 2019 12:16 AM UTC
And Nodelman expects macro risks could affect companies’ ability to raise capital.

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled back into biotech, and lack of growth opportunities elsewhere. Buysiders are optimistic the sector will keep up with if not outpace the broader markets -- particularly if the M&A rally continues.

The first week of the new quarter has already seen a spate of new deals, including an M&A transaction and an IPO from companies working on non-alcoholic steatohepatitis (NASH) programs...

BCIQ Company Profiles

Biogen Inc.

Celgene Corp.